Abstract
Breast cancer is the most common cause of cancer deaths in women. Recurrent breast cancer is not curable by standard therapies and new therapeutic approaches are needed. The goal of this study is to employ an alternative and safe approach to immunotherapy of breast cancer patients using monoclonal anti-idiotype (Id) antibodies in two conceptually different ways. In the first approach, monoclonal anti-Id antibodies which mimic breast cancer tumor-associated antigens (TAA) will be used to actively immunize patients for the production of anti-tumor immunity. In the second approach, monoclonal anti-Id antibodies will be used to remove unwanted excess radioactivity from the circulation of patients previously treated with radiolabeled monoclonal anti-breast TAA antibodies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
E. Debus, R. Moll, W.W. Frank, K. Weber, and M. Osborn. Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am. J. Pathol. 114: 121 (1984).
A.M. Gown and A.M. Vogel. Monoclonal antibodies to human intermediate filament proteins. III. Analysis of tumors. Am. J. Clin. Pathol. 84: 413–424 (1985).
G. Pancino, C. Charpin, F. Calvo, M.C. Guillemin, and A. Roseto. A novel monoclonal antibody (7B10) with differential reactivity between human mammary carcinoma and normal breast. Cancer Res. 47: 4444–4452 (1987).
D.P. Edwards, K.T. Grzyb, L.G. Dressier, R.E. Mansel, D.T. Zava, G.W. Sledge, Jr., and M.L. McGuire. Monoclonal antibody identification and characterization of a MW 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res. 46: 1306–1317 (1986).
C.A. White, R. Dulbecc, R. Allen, M. Bowman, and B. Armstrong. Two monoclonal antibodies selective for human mammary carcinoma. Cancer Res. 45: 1337–1343 (1985).
R.L. Ceriani and E.H. Rosenbaum. Breast epithelial antigens in the circulations of breast cancer patients. Immunol. Ser. 53: 223–241 (1990).
A.D. Thor and S.M. Edgerton. Monoclonal antibodies reactive with human breast or ovarian carcinoma: in vivo applications. Semin. Nucl. Med. 19: 295–308 (1989).
R.L. Ceriani, J.A. Peterson, J.Y. Lee, R. Moncada and E.W. Blank. Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule. Somatic Cell Genetics 9: 415–427 (1983).
J. Taylor-Papadimitriou, J.A. Peterson, J. Arklie, J. Burchell, R.L. Ceriani, and W.F. Bodmer. Monoclonal antibodies to epithelium specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int. J. Cancer 28: 17–21 (1981).
N.K. Jerne. Towards a network theory of the immune system. Ann. Immunol. 125C: 373–389 (1974).
A. Nisonoff and E. Lamoyi. Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: possible application to vaccine production. Clin. Immunol. Immunopathol. 21: 397–406 (1981).
H. Kohler, S. Muller, and C. Bona. Internal antigen and the immune network. Proc. Soc. Exp. Biol. Med. 178: 189–193 (1985).
N.K. Jerne, J. Roland, and A. Cazenave. Recurrent idiotypes and internal images. EMBO J. 1: 243–248 (1982).
C.A. Bona, and H. Kohler. Anti-idiotpic antibodies and internal images. In: Probes for Receptor Structure and Function. Vol. 4, edited by J.C. Venter, CM. Fraser and J. Lindstrom, New York: Alan R. Liss, 141–150 (1984).
H. Kohler, T. Kieber-Emmons, S. Srinivasan, S. Kaveri, W.J.W. Morrow, S. Muller, C. Kang, and S. Raychaudhuri. Revised immune network concepts. Clin. Immunol. Immunopath. 52: 104–116 (1989).
S.E. Order, G.B. Still wagon, J.L. Klein, et al. Iodine-131-antiferritin, a new treatment modality in hepatomas: a radiation therapy oncology group study. J. Clin. Oncol. 3: 1573–1582 (1984).
R.E. Lenard, S.E. Order, J.J. Spunberg, S.O. Asbell, and D.A. Leibel. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin’s disease. J. Clin. Oncol. 3: 1296–1300 (1985).
S.M. Larson, J. A. Carrasquillo, K.A. Krohn, et al. Localization of 1-131-labeled p97 specific Fab fragments in human melanomas as a basis for radiotherapy. J. Clin. Invest. 72: 2101–2114 (1983).
S.J. DeNardo, L.F. O’Grady, G.L. DeNardo, S.L. Mills, and D.J. Macey. Radioimmunotherapy of lymphoproliferative disease. Blood 72: 241 (1988) (abstract).
S. Rosen, A.M. Zimmer, R. Goldman-Neiken, et al. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an I-131-labeled monoclonal antibody: An Illinois Cancer Council Study. J. Clin. Oncol. 5: 562–573 (1987).
M. Bhattacharya-Chatterjee, M.W. Pride, B.K. Seon, and H. Kohler. Idiotype vaccines against human T cell acute lymphoblastic leukemia (T-ALL). I. Generation and characterizations of biologically active monoclonal anti-idiotopes. J. Immunol. 139: 1354–1360 (1987).
M. Bhattacharya-Chatterjee, S.K. Chatterjee, S. Vasile, B.K. Seon, and H. Kohler. Idiotype vaccines against human T cell leukemia. II. Generation and characterization of a monoclonal idiotype cascade (Ab1, Ab2 and Ab3). J. Immunol. 141: 1398–1403 (1988).
M. Bhattacharya-Chatterjee, S. Mukerjee, W. Biddle, K.A. Foon, and H. Kohler. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J. Immunol. 145: 2758–2765 (1990).
M. Bhattacharya-Chatterjee, K.A. Foon, and H. Kohler. Anti-idiotype monoclonal antibodies as vaccines for human cancer. Intern. Rev. Immunol. 7: 289–302 (1991).
K.A. Foon, L. Vaickus, A. Oseroff, H. Stoll, E. Mrozek, D. Russel, H. Kohler, and M. Chatterjee. Clinical response to anti-idiotype monoclonal antibody vaccine therapy for patients with cutaneous T cell lymphoma. 34th Annual Meeting, Am. Soc. Hematol. 1992 [Abstract].
A. Mittelman, Z.J. Chen, T. Kageshita, H. Yang, M. Yamada, P. Baskind, N. Goldberg, C. Puccio, T. Ahmed, Z. Arlin, and S. Ferrone. Active specific immunotherapy in patients with melanoma: A clinical trial with murine anti-idiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular weight melanoma-associated antigen monoclonal antibodies. J. Clin. Invest. 86: 2136–2144 (1990).
A. Mittelman, Z.J. Chen, H. Yang, G. Wong, and S. Ferrone. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA 89: 466–470 (1992).
D. Herlyn, M. Wettendorf, E. Schmoll, D. Hopoulos, I. Schedel, U. Dreikhausen, R. Raab, A.H. Ross, H. Jaksche, M. Scriba, and H. Koprowski. Anti-idiotype immunization of cancer patients: Modulation of immune response. Proc. Natl. Acad. Sci. USA 84: 8055–8059 (1987).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bhattacharya-Chatterjee, M., Mrozek, E., Mukerjee, S., Ceriani, R.L., Kohler, H., Foon, K.A. (1994). Anti-Idiotype Antibodies as Potential Therapeutic Agents for Human Breast Cancer. In: Ceriani, R.L. (eds) Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment. Advances in Experimental Medicine and Biology, vol 353. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2443-4_13
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2443-4_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6038-4
Online ISBN: 978-1-4615-2443-4
eBook Packages: Springer Book Archive